Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a two-drug cocktail in patients with MET-dysregulated advanced solid tumors: A phase I, multicenter, open-label, single-sequence drug-drug interaction study -
Capmatinib has a broad range of antiviral activity against human... | Download Scientific Diagram
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors - Clinical Therapeutics
Capmatinib + Nazartinib for EGFR-Mutant NSCLC - Journal of Oncology Navigation & Survivorship
Capmatinib (INC280) | c-MET Kinase Inhibitor | MedChemExpress
Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer
PDF) Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
Tabrecta (capmatinib)
Schematic representation of MET signaling blockade by capmatinib.... | Download Scientific Diagram
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
2 Synopsis
TABRECTA® (capmatinib) tablets | Health Care Providers
Dosing & Administration | TABRECTA® (capmatinib) tablets
Tabreta (capmatinib) Cancer Medication - Cancer Health
capmatinib (Tabrecta™)
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer | JCO Precision Oncology
Capmatinib | Memorial Sloan Kettering Cancer Center
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Tabrecta (Capmatinib) 200mg Tablet – Apothera
Tabrecta (capmatinib)
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
capmatinib
Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer
SAFETY, DOSING, AND ADMINISTRATION
